List view / Grid view
8 April 2015 | By Victoria White
Gilead has submitted a NDA to the FDA for an investigational fixed-dose combination of F/TAF for the treatment of HIV-1 infection...
24 March 2015 | By Victoria White
Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled the EU Disease Lens: a digital dashboard that brings insight into 15 major diseases...
23 March 2015 | By Victoria White
Heparin, a blood thinning agent, is helping researchers at the University of East Anglia (UEA) understand more about the body’s natural barriers to HIV...
27 February 2015 | By Gilead Sciences
96 percent SVR12 rate for hepatitis C genotypes 1 and 4 among HIV-infected patients on antiretroviral therapy...
27 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced results from ALLY-2, a Phase III clinical trial evaluating the investigational once-daily combination of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) coinfected with HIV – a patient population that historically has been challenging to treat in large part due…
26 February 2015 | By GAFFI
Early detection and treatment of fungal meningitis and pneumonia can save hundreds of thousands of lives, for a cost of 'only $30' per HIV patient, the world's first stakeholder meeting on fungal diseases hosted by GAFFI (Global Action Fund for Fungal Infections) and held in Seattle, USA has concluded...
12 February 2015 | By KU Leuven
Writing in the journal EBioMedicine, researchers at KU Leuven’s Laboratory for Clinical and Epidemiological Virology now report a recombinant form of HIV observed in patients in Cuba that makes this transition much faster...
30 January 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has approved Evotaz (atazanavir 300 mg and cobicistat 150 mg) tablets in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults...
2 December 2014 | By MWV
Global packaging company has received a grant from The Bill & Melinda Gates Foundation to improve adherence and accuracy during PrEP trials...
27 November 2014 | By ViiV Healthcare
Landmark number of grants awarded for 2015 as the Positive Action for Children Fund hits 5 year milestone...
29 September 2014 | By Janssen
Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a Positive Opinion recommending REZOLSTA™...
26 September 2014 | By Roche
Roche announced the launch of a new Global Access Program for HIV viral load testing...
24 September 2014 | By Gilead
Gilead Sciences, Inc. announced that two Phase 3 clinical trials (Studies 104 and 111) evaluating an investigational once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection in treatment-naïve adults met their primary objectives...
5 September 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the European Commission has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets...
27 September 2013 | By Gilead Sciences, Inc.
Tybost™ is a new Bbosting agent for HIV therapy which facilitates once-daily dosing of the protease inhibitors Atazanavir and Darunavir...
